替吉奥联合顺铂方案对比DP方案一线治疗EGFR野生型的晚期非小细胞肺癌的临床观察

Clinical Observation of the Combination of Tegio and Cisplatin in the first-line Treatment of EGFR Wild-type Advanced Non-small Cell Lung Cancer

目的对比替吉奥联合顺铂与DP方案一线治疗EGFR野生型晚期非小细胞肺癌的效果。方法60例EGFR野生型晚期非小细胞肺癌患者在自愿前提下参与此次研究,均在2019年6月至2020年5月期间经我院肿瘤中心确诊。本研究以先对比、后分析的形式展开,以分组(对照组、研究组)、不同治疗措施(对照组为多西他赛联合顺铂,研究组为替吉奥联合顺铂)的实施来达到对比的目的,以统计患者观察指标(近期疗效、不良反应、PFS(无进展生存期)及中位生存期)来达到分析治疗措施效果的目的。结果对照组、研究组近期疗效分别为40%(12/30)、46.67%(14/30),组间疗效无差异性(P>0.05);对照组患者乏力、粒细胞减少不良反应发生率显著高于研究组患者(P<0.05),其余不良反应的发生率无差异性(P>0.05);组间PFS及中位生存期无显著差异(P>0.05)。结论对于EGFR野生型晚期非小细胞肺癌患者的治疗来说,替吉奥联合顺铂比DP方案有着更理想的治疗价值,不良反应发生率更低,因此可进行应用。

Objective To compare the efficacy of tegio combined with cisplatin and DP regimen in first-line treatment of EGFR wild-type advanced non-small cell lung cancer.Methods Sixty patients with EGFR wild-type advanced non-small cell lung cancer participated in this study on a voluntary basis,and all of them were diagnosed by our cancer center from June 2019 to May 2020.This study was carried out in the form of comparison and analysis followed by the implementation of grouping(control group,research group)and different treatment measures(control group is docetaxel combined with cisplatin,and the research group is tezio combined with cisplatin)To achieve the purpose of comparison,statistical analysis of patient observation indicators(short-term efficacy,adverse reactions,PFS(progression-free survival)and median survival)to achieve the purpose of analyzing the effects of treatment measures.Results The short-term efficacy of the control group and the research group were 40%(12/30)and 46.67%(14/30),respectively,and there was no difference in efficacy between the groups(P>0.05);the control group had fatigue and neutropenia.The rate was significantly higher than the patients in the study group(P<0.05),and there was no difference in the incidence of other adverse reactions(P>0.05);there was no significant difference in PFS and median survival between groups(P>0.05).Conclusion For the treatment of patients with EGFR wild-type advanced nonsmall cell lung cancer,Tiogio combined with cisplatin has a more ideal therapeutic value than the DP regimen,and the incidence of adverse reactions is lower,so it can be applied.